Abstract
We examined the pharmacokinetics of ganciclovir in different populations of cytomegalovirus (CMV)-infected patients through the use of nonlinear mixed-effects modelling. As expected, patient weight and estimated creatinine clearance were shown to be important covariates in the serum ganciclovir clearance. Unexpectedly, major differences in ganciclovir clearance between different populations of patients were found. Human immunodeficiency virus (HIV)-infected patients with CMV retinitis cleared ganciclovir 41% faster than HIV-infected patients only shedding CMV into the urine. Solid-organ transplant patients had a serum clearance one-fourth that of HIV-infected patients, even with correction for creatinine clearance. These findings require prospective validation and may have important implications for ganciclovir dosing in different populations of CMV-infected patients.
Full Text
The Full Text of this article is available as a PDF (153.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Causey D. Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: an approach to treatment. J Acquir Immune Defic Syndr. 1991;4 (Suppl 1):S16–S21. [PubMed] [Google Scholar]
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- Dieterich D. T., Kotler D. P., Busch D. F., Crumpacker C., Du Mond C., Dearmand B., Buhles W. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis. 1993 Feb;167(2):278–282. doi: 10.1093/infdis/167.2.278. [DOI] [PubMed] [Google Scholar]
- Dunn D. L., Mayoral J. L., Gillingham K. J., Loeffler C. M., Brayman K. L., Kramer M. A., Erice A., Balfour H. H., Jr, Fletcher C. V., Bolman R. M., 3rd Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 1991 Jan;51(1):98–106. doi: 10.1097/00007890-199101000-00015. [DOI] [PubMed] [Google Scholar]
- Erice A., Jordan M. C., Chace B. A., Fletcher C., Chinnock B. J., Balfour H. H., Jr Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 1987 Jun 12;257(22):3082–3087. [PubMed] [Google Scholar]
- Fletcher C., Sawchuk R., Chinnock B., de Miranda P., Balfour H. H., Jr Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986 Sep;40(3):281–286. doi: 10.1038/clpt.1986.177. [DOI] [PubMed] [Google Scholar]
- Kuppermann B. D., Quiceno J. I., Flores-Aguilar M., Connor J. D., Capparelli E. V., Sherwood C. H., Freeman W. R. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993 Dec;168(6):1506–1509. doi: 10.1093/infdis/168.6.1506. [DOI] [PubMed] [Google Scholar]
- Mayoral J. L., Loeffler C. M., Fasola C. G., Kramer M. A., Orrom W. J., Matas A. J., Najarian J. S., Dunn D. L. Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. Arch Surg. 1991 Feb;126(2):202–206. doi: 10.1001/archsurg.1991.01410260092013. [DOI] [PubMed] [Google Scholar]
- Sheiner L. B., Rosenberg B., Marathe V. V. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977 Oct;5(5):445–479. doi: 10.1007/BF01061728. [DOI] [PubMed] [Google Scholar]
- Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]